Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 372

1.

Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.

Bertaglia E, Blank B, Blomström-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P.

Europace. 2019 Aug 3. pii: euz172. doi: 10.1093/europace/euz172. [Epub ahead of print]

PMID:
31377792
2.

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Kerschnitzki M, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators.

BMC Cardiovasc Disord. 2019 Jul 12;19(1):165. doi: 10.1186/s12872-019-1144-x.

3.

Effect of Concomitant Atrial Fibrillation on In-Hospital Outcomes of Non-ST-Elevation-Acute Coronary Syndrome-Related Hospitalizations in the United States.

Mohamed MO, Kirchhof P, Vidovich M, Savage M, Rashid M, Kwok CS, Thomas M, El Omar O, Al Ayoubi F, Fischman DL, Mamas MA.

Am J Cardiol. 2019 Aug 15;124(4):465-475. doi: 10.1016/j.amjcard.2019.05.040. Epub 2019 May 31.

PMID:
31248589
4.

High-Throughput Analysis of Optical Mapping Data Using ElectroMap.

O'Shea C, Holmes AP, Yu TY, Winter J, Wells SP, Parker BA, Fobian D, Johnson DM, Correia J, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

J Vis Exp. 2019 Jun 4;(148). doi: 10.3791/59663.

PMID:
31233017
5.

Education as a vehicle towards quality improvement in the European Society of Cardiology.

Kirchhof P, Beeri R, Fox K, Grapsa J, Kotecha D.

Cardiovasc Res. 2019 Jul 1;115(8):e80-e81. doi: 10.1093/cvr/cvz055. No abstract available.

PMID:
31220211
6.

The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation.

Dudink EA, Weijs B, Tull S, Luermans JG, Fabritz L, Chua W, Rienstra M, Gelder ICV, Schotten U, Kirchhof P, Crijns HJ.

J Atr Fibrillation. 2018 Dec 31;11(4):2058. doi: 10.4022/jafib.2058. eCollection 2018 Dec.

7.

Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset.

Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Crijns HJGM, Haase D, Hatem S, Kääb S, Mont L, Schotten U, Sinner MF, Hemming K, Deeks JJ, Kirchhof P, Fabritz L.

BMC Cardiovasc Disord. 2019 May 21;19(1):120. doi: 10.1186/s12872-019-1105-4.

8.

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).

Rohla M, Weiss TW, Pecen L, Patti G, Siller-Matula JM, Schnabel RB, Schilling R, Kotecha D, Lucerna M, Huber K, De Caterina R, Kirchhof P.

BMJ Open. 2019 Mar 30;9(3):e022478. doi: 10.1136/bmjopen-2018-022478.

9.

Cardiac Optogenetics and Optical Mapping - Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology.

O'Shea C, Holmes AP, Winter J, Correia J, Ou X, Dong R, He S, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

Front Physiol. 2019 Mar 7;10:182. doi: 10.3389/fphys.2019.00182. eCollection 2019. Review.

10.

Clinical characteristics of heart failure patients undergoing atrial fibrillation ablation today in Europe. Data from the atrial fibrillation registries of the European Society of Cardiology and the European Heart Rhythm Association.

Temporelli PL, Tilz RR, Arbelo E, Dagres N, Laroche C, Crijns HJ, Blomstrom-Lundqvist C, Kirchhof P, Lip GYH, Boriani G, Pokushalov E, Nakou E, Brugada J, Tavazzi L.

Eur J Heart Fail. 2019 May;21(5):690-693. doi: 10.1002/ejhf.1458. Epub 2019 Mar 21. No abstract available.

PMID:
30896056
11.

MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies.

Herm J, Schurig J, Martinek MR, Höltgen R, Schirdewan A, Kirchhof P, Wieczorek M, Pürerfellner H, Heuschmann PU, Fiebach JB, Haeusler KG.

BMC Cardiovasc Disord. 2019 Mar 12;19(1):58. doi: 10.1186/s12872-019-1035-1.

12.

The Medical Profession, Industry, and Continuing Medical Education: Finding the Balance That's Right for Patients.

Kearney P, Simoons M, Ryden L, Kirchhof P, Pries A, O'Morain C, Bax JJ.

Am J Med. 2019 Mar 8. pii: S0002-9343(19)30221-9. doi: 10.1016/j.amjmed.2019.02.026. [Epub ahead of print] Review.

PMID:
30853472
13.

SMART About Watches: We Need Technical and Biological Validation of Atrial Fibrillation Screening.

Kalla M, Fabritz L, Kirchhof P.

JACC Clin Electrophysiol. 2019 Feb;5(2):209-211. doi: 10.1016/j.jacep.2018.11.018. No abstract available.

PMID:
30784692
14.

ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology.

O'Shea C, Holmes AP, Yu TY, Winter J, Wells SP, Correia J, Boukens BJ, De Groot JR, Chu GS, Li X, Ng GA, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

Sci Rep. 2019 Feb 4;9(1):1389. doi: 10.1038/s41598-018-38263-2.

15.

Digital learning and the future cardiologist.

Rosselló X, Stanbury M, Beeri R, Kirchhof P, Casadei B, Kotecha D.

Eur Heart J. 2019 Feb 7;40(6):499-501. doi: 10.1093/eurheartj/ehy884. No abstract available.

PMID:
30698713
16.

Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Ricci F, Kirchhof P, De Caterina R.

Am J Med. 2019 Jun;132(6):749-757.e5. doi: 10.1016/j.amjmed.2018.12.036. Epub 2019 Jan 19.

17.

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.

Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L.

Eur Heart J. 2019 Apr 21;40(16):1268-1276. doi: 10.1093/eurheartj/ehy815.

18.

Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.

De Caterina R, Kelly P, Monteiro P, Deharo JC, de Asmundis C, López-de-Sá E, Weiss TW, Waltenberger J, Steffel J, de Groot JR, Levy P, Bakhai A, Zierhut W, Laeis P, Reimitz PE, Kirchhof P; ETNA-AF-Europe investigators.

J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104. doi: 10.2459/JCM.0000000000000737.

PMID:
30540648
19.

Development and validation of a score to detect paroxysmal atrial fibrillation after stroke.

Uphaus T, Weber-Krüger M, Grond M, Toenges G, Jahn-Eimermacher A, Jauss M, Kirchhof P, Wachter R, Gröschel K.

Neurology. 2019 Jan 8;92(2):e115-e124. doi: 10.1212/WNL.0000000000006727. Epub 2018 Dec 7.

PMID:
30530796
20.

Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.

Kirchhof P, Bach M, Camm AJ.

J Am Coll Cardiol. 2018 Nov 13;72(20):2546-2547. doi: 10.1016/j.jacc.2018.09.024. No abstract available.

PMID:
30442303
21.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041.

PMID:
30423165
22.

Direct Oral Anticoagulants Halve Thromboembolic Events After Cardioversion of AF Compared With Warfarin.

Kotecha D, Pollack CV Jr, De Caterina R, Renda G, Kirchhof P.

J Am Coll Cardiol. 2018 Oct 16;72(16):1984-1986. doi: 10.1016/j.jacc.2018.07.083. No abstract available.

PMID:
30309478
23.

Roadmap for cardiovascular education across the European Society of Cardiology: inspiring better knowledge and skills, now and for the future.

Kotecha D, Bax JJ, Carrera C, Casadei B, Merkely B, Anker SD, Vardas PE, Kearney PP, Roffi M, Ros M, Vahanian A, Weidinger F, Beeri R, Budaj A, Calabrò P, Czerwińska-Jelonkiewicz K, D'Ascenzi F, De Potter T, Fox KF, Hartikainen J, McAdam B, Milicic D, Pasquet AA, Sionis A, Sohaib SMA, Tsioufis C, Verhorst PMJ, Kirchhof P; ESC Scientific Document Group ; 2016 ESC Education Conference .

Eur Heart J. 2019 Jun 1;40(21):1728-1738. doi: 10.1093/eurheartj/ehy058.

PMID:
30226525
24.

Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries.

Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R.

Int J Cardiol. 2018 Nov 1;270:160-166. doi: 10.1016/j.ijcard.2018.06.098. Epub 2018 Jun 28.

PMID:
30220376
25.

Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study.

Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C.

BMJ Open. 2018 Sep 10;8(9):e022690. doi: 10.1136/bmjopen-2018-022690.

26.

Safety and efficacy of uninterrupted vs. minimally interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: two sides of the same coin?

Di Biase L, Kirchhof P, Romero J.

Europace. 2019 Feb 1;21(2):181-183. doi: 10.1093/europace/euy172. No abstract available.

PMID:
30052953
27.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.

Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.

PMID:
30052894
28.

Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.

Romero J, Cerrud-Rodriguez RC, Diaz JC, Michaud GF, Taveras J, Alviz I, Grupposo V, Cerna L, Avendano R, Kumar S, Kirchhof P, Natale A, Di Biase L.

Europace. 2018 Oct 1;20(10):1612-1620. doi: 10.1093/europace/euy133.

PMID:
29982383
29.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

30.

Multi-ethnic genome-wide association study for atrial fibrillation.

Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, Almgren P, Alonso A, Anderson CD, Aragam KG, Arking DE, Barnard J, Bartz TM, Benjamin EJ, Bihlmeyer NA, Bis JC, Bloom HL, Boerwinkle E, Bottinger EB, Brody JA, Calkins H, Campbell A, Cappola TP, Carlquist J, Chasman DI, Chen LY, Chen YI, Choi EK, Choi SH, Christophersen IE, Chung MK, Cole JW, Conen D, Cook J, Crijns HJ, Cutler MJ, Damrauer SM, Daniels BR, Darbar D, Delgado G, Denny JC, Dichgans M, Dörr M, Dudink EA, Dudley SC, Esa N, Esko T, Eskola M, Fatkin D, Felix SB, Ford I, Franco OH, Geelhoed B, Grewal RP, Gudnason V, Guo X, Gupta N, Gustafsson S, Gutmann R, Hamsten A, Harris TB, Hayward C, Heckbert SR, Hernesniemi J, Hocking LJ, Hofman A, Horimoto ARVR, Huang J, Huang PL, Huffman J, Ingelsson E, Ipek EG, Ito K, Jimenez-Conde J, Johnson R, Jukema JW, Kääb S, Kähönen M, Kamatani Y, Kane JP, Kastrati A, Kathiresan S, Katschnig-Winter P, Kavousi M, Kessler T, Kietselaer BL, Kirchhof P, Kleber ME, Knight S, Krieger JE, Kubo M, Launer LJ, Laurikka J, Lehtimäki T, Leineweber K, Lemaitre RN, Li M, Lim HE, Lin HJ, Lin H, Lind L, Lindgren CM, Lokki ML, London B, Loos RJF, Low SK, Lu Y, Lyytikäinen LP, Macfarlane PW, Magnusson PK, Mahajan A, Malik R, Mansur AJ, Marcus GM, Margolin L, Margulies KB, März W, McManus DD, Melander O, Mohanty S, Montgomery JA, Morley MP, Morris AP, Müller-Nurasyid M, Natale A, Nazarian S, Neumann B, Newton-Cheh C, Niemeijer MN, Nikus K, Nilsson P, Noordam R, Oellers H, Olesen MS, Orho-Melander M, Padmanabhan S, Pak HN, Paré G, Pedersen NL, Pera J, Pereira A, Porteous D, Psaty BM, Pulit SL, Pullinger CR, Rader DJ, Refsgaard L, Ribasés M, Ridker PM, Rienstra M, Risch L, Roden DM, Rosand J, Rosenberg MA, Rost N, Rotter JI, Saba S, Sandhu RK, Schnabel RB, Schramm K, Schunkert H, Schurman C, Scott SA, Seppälä I, Shaffer C, Shah S, Shalaby AA, Shim J, Shoemaker MB, Siland JE, Sinisalo J, Sinner MF, Slowik A, Smith AV, Smith BH, Smith JG, Smith JD, Smith NL, Soliman EZ, Sotoodehnia N, Stricker BH, Sun A, Sun H, Svendsen JH, Tanaka T, Tanriverdi K, Taylor KD, Teder-Laving M, Teumer A, Thériault S, Trompet S, Tucker NR, Tveit A, Uitterlinden AG, Van Der Harst P, Van Gelder IC, Van Wagoner DR, Verweij N, Vlachopoulou E, Völker U, Wang B, Weeke PE, Weijs B, Weiss R, Weiss S, Wells QS, Wiggins KL, Wong JA, Woo D, Worrall BB, Yang PS, Yao J, Yoneda ZT, Zeller T, Zeng L, Lubitz SA, Lunetta KL, Ellinor PT.

Nat Genet. 2018 Jun 11;50(9):1225-1233. doi: 10.1038/s41588-018-0133-9.

31.

Symptom Burden of Atrial Fibrillation and Its Relation to Interventions and Outcome in Europe.

Schnabel RB, Pecen L, Rzayeva N, Lucerna M, Purmah Y, Ojeda FM, De Caterina R, Kirchhof P.

J Am Heart Assoc. 2018 May 18;7(11). pii: e007559. doi: 10.1161/JAHA.117.007559.

32.

Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.

Siller-Matula JM, Pecen L, Patti G, Lucerna M, Kirchhof P, Lesiak M, Huber K, Verheugt FWA, Lang IM, Renda G, Schnabel RB, Wachter R, Kotecha D, Sellal JM, Rohla M, Ricci F, De Caterina R; TEAM in AF group.

Int J Cardiol. 2018 Aug 15;265:141-147. doi: 10.1016/j.ijcard.2018.04.093. Epub 2018 Apr 22.

PMID:
29706429
33.

Expert opinion paper on atrial fibrillation detection after ischemic stroke.

Haeusler KG, Gröschel K, Köhrmann M, Anker SD, Brachmann J, Böhm M, Diener HC, Doehner W, Endres M, Gerloff C, Huttner HB, Kaps M, Kirchhof P, Nabavi DG, Nolte CH, Pfeilschifter W, Pieske B, Poli S, Schäbitz WR, Thomalla G, Veltkamp R, Steiner T, Laufs U, Röther J, Wachter R, Schnabel R.

Clin Res Cardiol. 2018 Oct;107(10):871-880. doi: 10.1007/s00392-018-1256-9. Epub 2018 Apr 27. Review.

PMID:
29704214
34.

Is there a CASTLE-AF on the hill?

Bono J, Kirchhof P.

Eur Heart J. 2018 Apr 21;39(16):1324-1325. doi: 10.1093/eurheartj/ehy172. No abstract available.

PMID:
29688436
35.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

36.

Nitrite circumvents platelet resistance to nitric oxide in patients with heart failure preserved ejection fraction and chronic atrial fibrillation.

Borgognone A, Shantsila E, Worrall SM, Prompunt E, Loka T, Loudon BL, Chimen M, Ed Rainger G, Lord JM, Turner A, Nightingale P, Feelisch M, Kirchhof P, Lip GYH, Watson SP, Frenneaux MP, Madhani M.

Cardiovasc Res. 2018 Aug 1;114(10):1313-1323. doi: 10.1093/cvr/cvy087.

37.

Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation.

Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G, Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini JP, De Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di Biase L.

Eur Heart J. 2018 Aug 21;39(32):2942-2955. doi: 10.1093/eurheartj/ehy176.

38.

Atrial fibrillation patterns are associated with arrhythmia progression and clinical outcomes.

B Schnabel R, Pecen L, Engler D, Lucerna M, Sellal JM, Ojeda FM, De Caterina R, Kirchhof P.

Heart. 2018 Oct;104(19):1608-1614. doi: 10.1136/heartjnl-2017-312569. Epub 2018 Mar 17.

PMID:
29550771
39.

The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial.

Verma A, Ha ACT, Kirchhof P, Hindricks G, Healey JS, Hill MD, Sharma M, Wyse DG, Champagne J, Essebag V, Wells G, Gupta D, Heidbuchel H, Sanders P, Birnie DH.

Am Heart J. 2018 Mar;197:124-132. doi: 10.1016/j.ahj.2017.12.007. Epub 2017 Dec 8.

PMID:
29447772
40.

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.

Pavlovic D, Kirchhof P, Fabritz L.

Eur Heart J. 2018 Aug 21;39(32):2997-2999. doi: 10.1093/eurheartj/ehy018. No abstract available.

41.

Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J.

Front Pharmacol. 2018 Jan 22;9:13. doi: 10.3389/fphar.2018.00013. eCollection 2018.

42.

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Europace. 2018 Mar 1;20(3):395-407. doi: 10.1093/europace/eux318.

43.

Stratified prevention: opportunities and limitations. Report on the 1st interdisciplinary cardiovascular workshop in Augsburg.

Kirchhof G, Lindner JF, Achenbach S, Berger K, Blankenberg S, Fangerau H, Gimpel H, Gassner UM, Kersten J, Magnus D, Rebscher H, Schunkert H, Rixen S, Kirchhof P.

Clin Res Cardiol. 2018 Mar;107(3):193-200. doi: 10.1007/s00392-017-1186-y. Epub 2017 Dec 16. Review.

44.

Training the next generation of cardiovascular leaders in health policy and economics.

Naci H, Kirchhof P, Vahanian A, Steffel J, Bardinet I, Mossialos E, Vardas P.

Eur Heart J. 2017 Dec 1;38(45):3332-3335. doi: 10.1093/eurheartj/ehx673. No abstract available.

PMID:
29206965
45.

Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?

Piccini JP, Kirchhof P.

Eur Heart J. 2018 Feb 7;39(6):450-452. doi: 10.1093/eurheartj/ehx567. No abstract available.

PMID:
29182747
46.

Outcome of left atrial appendage occlusion in high-risk patients.

Masoud A, Bartoletti S, Fairbairn T, Khurana A, Velavan P, Morrison WL, Khalatbari A, Aggarwal S, Sharma N, Kirchhof P, Gupta D.

Heart. 2018 Apr;104(7):594-599. doi: 10.1136/heartjnl-2017-312383. Epub 2017 Nov 9.

PMID:
29122931
47.

Recent advances in rhythm control for atrial fibrillation.

Bond R, Olshansky B, Kirchhof P.

F1000Res. 2017 Oct 3;6:1796. doi: 10.12688/f1000research.11061.1. eCollection 2017. Review.

48.

European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers.

Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P; European Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium and the European Heart Rhythm Association (EHRA).

Europace. 2018 Feb 1;20(2):225-233. doi: 10.1093/europace/eux299. Review.

49.

Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.

Camm AJ, Turpie AGG, Hess S, Amarenco P, Lambelet M, Haas S, van Eickels M, Kirchhof P; XANTUS Investigators.

Europace. 2018 Jun 1;20(6):e87-e95. doi: 10.1093/europace/eux127.

PMID:
29016755
50.

Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.

De Caterina R, Brüggenjürgen B, Darius H, Köhler S, Lucerna M, Pecen L, Renda G, Schilling RJ, Schliephacke T, Zamorano JL, Le Heuzey JY, Kirchhof P.

Arch Cardiovasc Dis. 2018 Feb;111(2):74-84. doi: 10.1016/j.acvd.2017.04.007. Epub 2017 Sep 21.

Supplemental Content

Loading ...
Support Center